Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia

• Published in: Anales de Pediatría 2022-04, Vol.96 (4), p.309-318
• Main Authors: Galán Gómez, Víctor, de la Fuente Regaño, Lydia, Rodríguez Villa, Antonia, Díaz de Heredia Rubio, Cristina, González Vicent, Marta, Badell Serra, Isabel, María Fernández, José, Isabel Pascual Martínez, Antonia, María Pérez Hurtado, José, López Duarte, Mónica, Soledad Maldonado Regalado, M., Pérez-Martínez, Antonio
• Format: Article
• Language: English
• Subjects: Acute Disease; Acute lymphoblastic leukemia; BCR/ABL; Child; Cromosoma de Philadelphia; Enfermedad de injerto contra receptor; Graft versus host disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib; Imatinib Mesylate - therapeutic use; Leucemia linfoblástica aguda; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Trasplante de progenitores hematopoyéticos
• ISSN: 2341-2879; 2341-2879
• DOI: 10.1016/j.anpede.2021.02.016

Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT). The role of allogeneic HSCT in Ph-ALL patients has been analysed through a multicentric study where data belonging to 70 patients diagnosed of this entity in different centers that received HSCT between years 1998 and 2014, were reported by the Grupo Español de Trasplante Hematopoyético (GETH). The performance of HSCT from year 2004, in first complete remission (CR) status with thymoglobulin (ATG) based conditioning had a favorable impact on overall survival (OS). HSTC performance from year 2004, in first CR with ATG-based conditioning in addition to acute graft versus host disease (aGvHD) development, increased event free survival (EFS). Treatment with imatinib as well as undetectable minimal residual disease (MRD) prior to HSCT, combined with aGvHD, reduced risk of relapse (RR). Patient age less than 10 years when HSCT, first CR and ATG-based conditioning were associated to a lower transplant related mortality (TRM). Patients that could achieve first CR that also received ATG-based conditioning had a better OS and EFS, so HSCT should be considered for this group of patients. Los resultados de los pacientes con diagnóstico de leukemia linfoblástica aguda con cromosoma de Philadelphia (LLA-Ph) continúan siendo desfavorables comparados con los otros tipos de leucemias linfoblásticas agudas, pese a las mejoras en los tratamientos farmacológicos y los avances del trasplante de progenitores hematopoyéticos (TPH). Se ha analizado el papel del TPH alogénico en pacientes diagnosticados de LLA-Ph mediante un estudio multicéntrico donde se recogen datos pertenecientes a 70 pacientes reportados por el Grupo Español de Trasplante Hematopoyético (GETH ), diagnosticados de esta enfermedad trasplantados en distintos hospitales españoles entre los años 1998 y 2014. La realización del TPH a partir del año 2004, en primera remisión completa (RC) y con el empleo de timoglobulina (ATG) como parte del acondicionamiento, impactó favorablemente en la supervivencia global (SG). El TPH a partir del año 2004 en primera RC, así como el tratamiento con ATG y el desarrollo de enfermedad de injerto contra receptor aguda (EICRa), aumentaron la supervivencia libre de eventos (SLE). La administración